Foamy viruses - A world apart

Current Opinion in Microbiology

Volumn 7, Issue 4, 2004, Pages 400-406

  Delelis, Olivier ^a   Lehmann Che, Jacqueline ^a   Saïb, Ali ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

CELL ACTIVITY; CELL CULTURE; DISEASE TRANSMISSION; DNA SYNTHESIS; HEPATITIS B VIRUS; HUMAN; KIDNEY; MONKEY; NONHUMAN; RETROPOSON; RETROVIRUS; REVIEW; SPUMA VIRUS; VIRUS REPLICATION;

ANIMALS; RETROVIRIDAE INFECTIONS; SPUMAVIRUS; VIRUS REPLICATION;

BOS TAURUS; EQUIDAE; FELIS CATUS; HEPATITIS B VIRUS; HUMAN SPUMARETROVIRUS; MAMMALIA; PRIMATES; SIMIAE;

EID: 4143110105     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2004.06.009     Document Type: Review

References (61)

1. C.D. Meiering, and M.L. Linial Historical perspective of foamy virus epidemiology and infection Clin Microbiol Rev 14 2001 165 176
2. M. Picard-Maureau, G. Jarmy, A. Berg, A. Rethwilm, and D. Lindemann Foamy virus envelope glycoprotein-mediated entry involves a pH-dependent fusion process J Virol 77 2003 4722 4730
3. B. Sodeik Mechanisms of viral transport in the cytoplasm Trends Microbiol 8 2000 465 472
4. A. Saib, F. Puvion-Dutilleul, M. Schmid, J. Peries, and H. de The Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step J Virol 71 1997 1155 1161
5. C. Petit, M.L. Giron, J. Tobaly-Tapiero, P. Bittoun, E. Real, Y. Jacob, N. Tordo, H. De The, and A. Saib Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8 J Cell Sci 116 2003 3433 3442 This study, together with [4], shows, for the first time, the association of retroviral Gag molecules with the MTOC, highlighting a centriolar step of incoming FV particles. Co-localization of MTOC and Gag were demonstrated using indirect immunofluorescence in infected cells and EM analysis. A direct interaction between Gag and LC8 constitutes one of the molecular bases of such trafficking.
6. B.L. Goode, D.G. Drubin, and G. Barnes Functional cooperation between the microtubule and actin cytoskeletons Curr Opin Cell Biol 12 2000 63 71
7. D. McDonald, M.A. Vodicka, G. Lucero, T.M. Svitkina, G.G. Borisy, M. Emerman, and T.J. Hope Visualization of the intracellular behavior of HIV in living cells J Cell Biol 159 2002 441 452
8. T. Igakura, J.C. Stinchcombe, P.K. Goon, G.P. Taylor, J.N. Weber, G.M. Griffiths, Y. Tanaka, M. Osame, and C.R. Bangham Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton Science 299 2003 1713 1716
9. M.L. Giron, S. Colas, J. Wybier, F. Rozain, and R. Emanoil-Ravier Expression and maturation of human foamy virus Gag precursor polypeptides J Virol 71 1997 1635 1639
10. G.R. Whittaker, M. Kann, and A. Helenius Viral entry into the nucleus Annu Rev Cell Dev Biol 16 2000 627 651
11. A. Mergia, and M. Heinkelein Foamy virus vectors Curr Top Microbiol Immunol 277 2003 131 159
12. N.C. Josephson, G. Vassilopoulos, G.D. Trobridge, G.V. Priestley, B.L. Wood, T. Papayannopoulou, and D.W. Russell Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors Proc Natl Acad Sci USA 99 2002 8295 8300 This study, together with [13], clearly describes the transduction efficiency of FV-derived vector in the case of hematopoietic stem cells, either of murine or human origin. The transduction was demonstrated by long-term transgene expression in first and second transplant-recipient mice without gene silencing, demonstrating that FV-derived vectors might be a safe and effective alternative to MLV or lentivirus vectors in human gene therapy.
13. G. Vassilopoulos, G. Trobridge, N.C. Josephson, and D.W. Russell Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors Blood 98 2001 604 609
14. G. Trobridge, and D.W. Russell Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors J Virol 78 2004 2327 2335 This study compares the transduction frequencies of onco, lenti and FV vectors containing the same transgene under the same promoter, in the same cellular system. This is the first direct comparison of vectors of the three classes of retroviruses. It illustrates that both the cellular activation state and the progression through the cell cycle regulate the ability of retroviral vectors to efficiently deliver the foreign transgenes. Finally, they suggest that FV vectors might be the best choice for ex vivo stem cell gene therapy because they are equal to HIV vectors, but without safety concerns, and superior to MLV vectors in their ability to transduce transiently quiescent cells.
15. J.J. Kupiec, and P. Sonigo Reverse transcriptase jumps and gaps J Gen Virol 77 1996 1987 1991
16. V. Zennou, C. Petit, D. Guetard, U. Nerhbass, L. Montagnier, and P. Charneau HIV-1 genome nuclear import is mediated by a central DNA flap Cell 101 2000 173 185
17. J.D. Dvorin, P. Bell, G.G. Maul, M. Yamashita, M. Emerman, and M.H. Malim Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import J Virol 76 2002 12087 12096
18. C.H. Lecellier, and A. Saib Foamy viruses: between retroviruses and pararetroviruses Virology 271 2000 1 8
19. M. Lochelt, R.M. Flugel, and M. Aboud The human foamy virus internal promoter directs the expression of the functional Bel 1 transactivator and Bet protein early after infection J Virol 68 1994 638 645
20. S.F. Yu, D.N. Baldwin, S.R. Gwynn, S. Yendapalli, and M.L. Linial Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses Science 271 1996 1579 1582
21. M. Nassal, and H. Schaller Hepatitis B virus replication Trends Microbiol 1 1993 221 228
22. M.L. Linial, and S.W. Eastman Particle assembly and genome packaging Curr Top Microbiol Immunol 277 2003 89 110
23. A. Moebes, J. Enssle, P.D. Bieniasz, M. Heinkelein, D. Lindemann, M. Bock, M.O. McClure, and A. Rethwilm Human foamy virus reverse transcription that occurs late in the viral replication cycle J Virol 71 1997 7305 7311
24. S.F. Yu, M.D. Sullivan, and M.L. Linial Evidence that the human foamy virus genome is DNA J Virol 73 1999 1565 1572
25. O. Delelis, A. Saib, and P. Sonigo Biphasic DNA synthesis in spumaviruses J Virol 77 2003 8141 8146
26. J. Enssle, A. Moebes, M. Heinkelein, M. Panhuysen, B. Mauer, M. Schweizer, D. Neumann-Haefelin, and A. Rethwilm An active foamy virus integrase is required for virus replication J Gen Virol 80 1999 1445 1452
27. C.D. Meiering, K.E. Comstock, and M.L. Linial Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells J Virol 74 2000 1718 1726
28. T. Juretzek, T. Holm, K. Gartner, S. Kanzler, D. Lindemann, O. Herchenroder, M. Picard-Maureau, M. Rammling, M. Heinkelein, and A. Rethwilm Foamy virus integration J Virol 78 2004 2472 2477
29. E.H. Mules, O. Uzun, and A. Gabriel In vivo Ty1 reverse transcription can generate replication intermediates with untidy ends J Virol 72 1998 6490 6503
30. M. Heinkelein, T. Pietschmann, G. Jarmy, M. Dressler, H. Imrich, J. Thurow, D. Lindemann, M. Bock, A. Moebes, and J. Roy Efficient intracellular retrotransposition of an exogenous primate retrovirus genome EMBO J 19 2000 3436 3445
31. H. Imrich, M. Heinkelein, O. Herchenroder, and A. Rethwilm Primate foamy virus Pol proteins are imported into the nucleus J Gen Virol 81 2000 2941 2947
32. S.F. Yu, K. Edelmann, R.K. Strong, A. Moebes, A. Rethwilm, and M.L. Linial The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains J Virol 70 1996 8255 8262
33. J. Roy, W. Rudolph, T. Juretzek, K. Gartner, M. Bock, O. Herchenroder, D. Lindemann, M. Heinkelein, and A. Rethwilm Feline foamy virus genome and replication strategy J Virol 77 2003 11324 11331
34. M. Heinkelein, M. Rammling, T. Juretzek, D. Lindemann, and A. Rethwilm Retrotransposition and cell-to-cell transfer of foamy viruses J Virol 77 2003 11855 11858
35. J. Enssle, N. Fischer, A. Moebes, B. Mauer, U. Smola, and A. Rethwilm Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle J Virol 71 1997 7312 7317
36. M. Zemba, T. Wilk, T. Rutten, A. Wagner, R.M. Flugel, and M. Lochelt The carboxy-terminal p3Gag domain of the human foamy virus Gag precursor is required for efficient virus infectivity Virology 247 1998 7 13
37. A.W. Schliephake, and A. Rethwilm Nuclear localization of foamy virus Gag precursor protein J Virol 68 1994 4946 4954
38. M. Nassal The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly J Virol 66 1992 4107 4116
39. G. Cristofari, D. Ficheux, and J.L. Darlix The GAG-like protein of the yeast Ty1 retrotransposon contains a nucleic acid chaperone domain analogous to retroviral nucleocapsid proteins J Biol Chem 275 2000 19210 19217
40. J. Tobaly-Tapiero, P. Bittoun, M.L. Giron, M. Neves, M. Koken, H. de The, and A. Saib Human foamy virus capsid formation requires an interaction domain in the N terminus of Gag J Virol 75 2001 4367 4375
41. S.W. Eastman, and M.L. Linial Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly J Virol 75 2001 6857 6864
42. N. Fischer, M. Heinkelein, D. Lindemann, J. Enssle, C. Baum, E. Werder, H. Zentgraf, J.G. Muller, and A. Rethwilm Foamy virus particle formation J Virol 72 1998 1610 1615
43. T. Pietschmann, M. Heinkelein, M. Heldmann, H. Zentgraf, A. Rethwilm, and D. Lindemann Foamy virus capsids require the cognate envelope protein for particle export J Virol 73 1999 2613 2621
44. T. Pietschmann, H. Zentgraf, A. Rethwilm, and D. Lindemann An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity J Virol 74 2000 4474 4482
45. D. Lindemann, T. Pietschmann, M. Picard-Maureau, A. Berg, M. Heinkelein, J. Thurow, P. Knaus, H. Zentgraf, and A. Rethwilm A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity J Virol 75 2001 5762 5771
46. T. Wilk, V. Geiselhart, M. Frech, S.D. Fuller, R.M. Flugel, and M. Lochelt Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain J Virol 75 2001 7995 8007
47. P.A. Goepfert, K.L. Shaw, G.D Ritter Jr., and M.J. Mulligan A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum J Virol 71 1997 778 784
48. E.O. Freed Viral late domains J Virol 76 2002 4679 4687
49. P.D. Bieniasz Restriction factors: a defense against retroviral infection Trends Microbiol 11 2003 286 291
50. M. Bock, M. Heinkelein, D. Lindemann, and A. Rethwilm Cells expressing the human foamy virus (HFV) accessory Bet protein are resistant to productive HFV superinfection Virology 250 1998 194 204
51. C.H. Lecellier, W. Vermeulen, F. Bachelerie, M.L. Giron, and A. Saib Intra- and intercellular trafficking of the foamy virus auxiliary Bet protein J Virol 76 2002 3388 3394
52. A. Saib, M.H. Koken, P. van der Spek, J. Peries, and H. de The Involvement of a spliced and defective human foamy virus in the establishment of chronic infection J Virol 69 1995 5261 5268
53. A. Saib, J. Peries, and H. de The A defective human foamy provirus generated by pregenome splicing EMBO J 12 1993 4439 4444
54. C.D. Meiering, and M.L. Linial Reactivation of a complex retrovirus is controlled by a molecular switch and is inhibited by a viral protein Proc Natl Acad Sci USA 99 2002 15130 15135
55. A. Saib, M. Neves, M.L. Giron, M.C. Guillemin, J. Valla, J. Peries, and M. Canivet Long-term persistent infection of domestic rabbits by the human foamy virus Virology 228 1997 263 268
56. A.R. Schroder, P. Shinn, H. Chen, C. Berry, J.R. Ecker, and F. Bushman HIV-1 integration in the human genome favors active genes and local hotspots Cell 110 2002 521 529 See annotation for [57][57((].
57. X. Wu, Y. Li, B. Crise, and S.M. Burgess Transcription start regions in the human genome are favored targets for MLV integration Science 300 2003 1749 1751 These studies, [56][56((] and [57][57((], highlight for the first time the integration pattern of HIV-1, MLV and derived vectors in the human genome, illustrating the risk of insertional mutagenesis when using them for gene therapy. The implication of this in the future use of retroviruses in gene therapy, is that either retroviral integration must be controlled to direct the proviral DNA to specific regions of the genome, or that other retroviral systems that are naturally harmless with regards to their integration must be found.
58. M. Neves, J. Peries, and A. Saib Study of human foamy virus proviral integration in chronically infected murine cells Res Virol 149 1998 393 401
59. K. Bothe, A. Aguzzi, H. Lassmann, A. Rethwilm, and I. Horak Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes Science 253 1991 555 557
60. W. Heneine, M. Schweizer, P. Sandstrom, and T. Folks Human infection with foamy viruses Curr Top Microbiol Immunol 277 2003 181 196
61. P. Bastone, U. Truyen, and M. Lochelt Potential of zoonotic transmission of non-primate foamy viruses to humans J Vet Med B Infect Dis Vet Public Health 50 2003 417 423